Aroa Biosurgery Ltd
ASX:ARX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Aroa Biosurgery Ltd
Net Issuance of Common Stock
Aroa Biosurgery Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Aroa Biosurgery Ltd
ASX:ARX
|
Net Issuance of Common Stock
NZ$10k
|
CAGR 3-Years
-94%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
Pacific Edge Ltd
NZX:PEB
|
Net Issuance of Common Stock
NZ$20.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-5%
|
|
Aroa Biosurgery Ltd
Glance View
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
See Also
What is Aroa Biosurgery Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
10k
NZD
Based on the financial report for Mar 31, 2025, Aroa Biosurgery Ltd's Net Issuance of Common Stock amounts to 10k NZD.
What is Aroa Biosurgery Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-49%
Over the last year, the Net Issuance of Common Stock growth was -91%. The average annual Net Issuance of Common Stock growth rates for Aroa Biosurgery Ltd have been -94% over the past three years , -49% over the past five years .
